| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net income | -12.9 | -9.0 |
| EPS (diluted, $ a share) | $-0.26 | $-0.22 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: BNTC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Benitec Biopharma Inc.: key numbers
- Share price
- $8.15Close, Nov 17
- Market cap
- $284M
- Shares outstanding
- 34.88MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Benitec Biopharma Inc.
All →Benitec Biopharma Financial Results
Benitec Biopharma reported financial results for its first fiscal quarter ended September 30, 2026, and announced a change in its fiscal year-end from June 30 to December 31. The company highlighted a 100% responder rate in its ongoing Phase 1b/2a study of BB-301 for OPMD and confirmed it remains on track to begin a pivotal trial in mid-2027.
- Term
- Q1 2027
“The consistency and durability of the clinical benefit observed to date continues to strengthen our conviction in the potential of BB-301 to meaningfully alter the course of OPMD-related dysphagia.”
Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer
Benitec Biopharma Clinical Trial Data
Benitec Biopharma announced positive interim Phase 1b/2a results for its gene therapy BB-301 in patients with Oculopharyngeal Muscular Dystrophy (OPMD). The data showed a 100% responder rate across both low and high dose cohorts, with the high dose group demonstrating greater relative improvements in throat emptying and swallowing capacity at the 3-month mark.
Benitec Biopharma M&A Deal with U.S. Food and Drug Administration
Benitec Biopharma provided a status and timeline update for its BB-301 program following a Type C meeting with the FDA. The company remains on track to initiate a pivotal study in mid-2027, with the final study design expected to be confirmed in Q1 2027 after the FDA reviews additional natural history data.
- Counterparty
- U.S. Food and Drug Administration
Benitec Biopharma Other 8-K Filing
Benitec Biopharma Inc. has formally engaged Ernst & Young LLP (EY) as its new independent registered public accounting firm for the fiscal year ending June 30, 2027. The engagement follows the completion of EY's client acceptance procedures and the execution of a formal engagement letter on September 29, 2026.
- Counterparty
- Ernst & Young LLP
Benitec Biopharma Other 8-K Filing
Benitec Biopharma Inc. has dismissed Baker Tilly US, LLP as its independent registered public accounting firm and appointed Ernst & Young LLP (EY) for the fiscal year ending June 30, 2027. The change was made as a matter of good corporate governance following a review process, and there were no reported disagreements with Baker Tilly regarding accounting principles or practices.
- Counterparty
- Ernst & Young LLP
Benitec Biopharma Financial Results
Benitec Biopharma reported financial results for the fiscal year ended June 30, 2026, ending the period with approximately $180 million in cash. The company provided a clinical update on its BB-301 program for OPMD-related dysphagia, noting that Cohort 2 is fully enrolled and a pivotal study is planned for initiation in mid-2027 following a Type C meeting with the FDA.
- Term
- FY2026
“This has been an important year of clinical execution for Benitec and for the continued development of BB-301. Over the course of the year, we completed the follow-up of all six patients in Cohort 1 and fully enrolled Cohort 2, while continuing the regulatory interactions required to prepare BB-301 for advancement into a pivotal trial.”
Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer
“The consistency and durability of the clinical benefit observed to date, together with the discussions we have had with the FDA regarding pivotal study plans, continue to strengthen our conviction in the potential of BB-301 to meaningfully alter the course of OPMD-related dysphagia.”
Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer